-
-
-
-
-
-
-
Myriad Genetics adds two genes to carrier screening panel
-
-
-
-
-
-
-
Scotiabank Downgrades Myriad Genetics (MYGN) to Sector Perform
-
-
-
-
-
-
-
Myriad Genetics (MYGN) PT Lowered to $16 at Morgan Stanley
-
-
-
-
-
-
-
Myriad Genetics (MYGN) and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
-
-
-
-
-
-
-
Myriad Genetics (MYGN) PT Lowered to $24 at Scotiabank
-
-
-
-
-
-
-
Stephens Reiterates Equal Weight Rating on Myriad Genetics (MYGN)
-
-
-
-
-
-
-
Myriad Genetics (MYGN) PT Raised to $40 at Wolfe Research
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

